Cartography Biosciences’ Post

🧱 Builders: Kevin Parker - President & CEO, Founder @ Cartography Biosciences Join us for an exclusive conversation with Kevin Parker, CEO and co-founder of Cartography Biosciences, on our latest podcast episode of BIOS Builders. Kevin delves into his transition from a Ph.D. at Stanford focusing on basic biology to launching a startup aimed at transforming cancer therapy with targeted immunotherapies and an innovative antigen atlas. This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Learn about the inception of Cartography Biosciences, the development of their transformative technology, and the challenges of navigating the biotech startup landscape amidst a global pandemic. Kevin's insights into the future of precision medicine, the importance of interdisciplinary teams, and the journey towards their first clinical programs offer invaluable lessons for anyone interested in the cutting edge of cancer research and the entrepreneurial journey in life sciences. Don't miss this deep dive into the mission, science, and strategy behind Cartography Biosciences' quest to expand the horizons of cancer treatment. Tune in: https://buff.ly/4f2OnmH This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Read more about the exciting partnership here: https://buff.ly/4cC0sxo #BiotechInnovation #PrecisionMedicine #CancerTherapy #StartupJourney #TargetedImmunotherapy #LifeSciences #Entrepreneurship #ClinicalResearch #FutureOfHealthcare #TechBio #BiotechStartup #CancerResearch #InterdisciplinaryTeams #PhDLife #InnovativeTechnology

🧱 Builders: Kevin Parker - President & CEO, Founder @ Cartography Biosciences Join us for an exclusive conversation with Kevin Parker, CEO and co-founder of Cartography Biosciences, on our latest podcast episode of BIOS Builders. Kevin delves into his transition from a Ph.D. at Stanford focusing on basic biology to launching a startup aimed at transforming cancer therapy with targeted immunotherapies and an innovative antigen atlas. This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Learn about the inception of Cartography Biosciences, the development of their transformative technology, and the challenges of navigating the biotech startup landscape amidst a global pandemic. Kevin's insights into the future of precision medicine, the importance of interdisciplinary teams, and the journey towards their first clinical programs offer invaluable lessons for anyone interested in the cutting edge of cancer research and the entrepreneurial journey in life sciences. Don't miss this deep dive into the mission, science, and strategy behind Cartography Biosciences' quest to expand the horizons of cancer treatment. Tune in: https://buff.ly/4f2OnmH This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Read more about the exciting partnership here: https://buff.ly/4cC0sxo #BiotechInnovation #PrecisionMedicine #CancerTherapy #StartupJourney #TargetedImmunotherapy #LifeSciences #Entrepreneurship #ClinicalResearch #FutureOfHealthcare #TechBio #BiotechStartup #CancerResearch #InterdisciplinaryTeams #PhDLife #InnovativeTechnology

🧱 Builders: Kevin Parker - President & CEO, Founder @ Cartography Biosciences Join us for an exclusive conversation with Kevin Parker, CEO and co-founder of Cartography Biosciences, on our latest podcast episode of BIOS Builders. Kevin delves into his transition from a Ph.D. at Stanford focusing on basic biology to launching a startup aimed at transforming cancer therapy with targeted immunotherapies and an innovative antigen atlas. This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Learn about the inception of Cartography Biosciences, the development of their transformative technology, and the challenges of navigating the biotech startup landscape amidst a global pandemic. Kevin's insights into the future of precision medicine, the importance of interdisciplinary teams, and the journey towards their first clinical programs offer invaluable lessons for anyone interested in the cutting edge of cancer research and the entrepreneurial journey in life sciences. Don't miss this deep dive into the mission, science, and strategy behind Cartography Biosciences' quest to expand the horizons of cancer treatment. Tune in: https://buff.ly/4f2OnmH This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Read more about the exciting partnership here: https://buff.ly/4cC0sxo #BiotechInnovation #PrecisionMedicine #CancerTherapy #StartupJourney #TargetedImmunotherapy #LifeSciences #Entrepreneurship #ClinicalResearch #FutureOfHealthcare #TechBio #BiotechStartup #CancerResearch #InterdisciplinaryTeams #PhDLife #InnovativeTechnology

🚀 We are accelerating! Sofinnova Partners and Gustave Roussy have joined forces to supercharge the acceleration of oncology startups in France. This strategic alliance taps the research excellence of Gustave Roussy, the leading European cancer center, and Sofinnova's five decades of experience in #lifesciences innovation. It is the first big step for our new Sofinnova #Biovelocita Strategy. Our mission is clear: to build a robust ecosystem for startups by leveraging Gustave Roussy's cutting-edge cancer research and Sofinnova's expertise in creating and nurturing innovative companies. We're committed to fostering a thriving French #biotech ecosystem and advancing cancer care on a global scale. This partnership represents a significant milestone in our collective journey towards transformative breakthroughs in oncology research and patient care. The future holds promising new molecules and innovative technologies that can redefine how we approach cancer treatment. Stay tuned for more updates as we embark on this exciting venture, with the first company set to emerge in early 2024. Together, we're making strides in the fight against cancer and shaping a brighter future for patients worldwide. Read more: https://hubs.ly/Q02cZsQk0 Gustave Roussy Fabrice Barlesi Christophe Javaud Graziano Seghezzi Maria Gabriella Camboni Matthieu Coutet Alex Leech Zhizhong "Joel" Y. Marie Duranteau Cristina Pelizon Silvano Spinelli #BiotechInnovation #Oncology #Biovelocita #GustaveRoussy #LifeSciences #Innovation #VC #acceleration #leadership

💵 Predicta Biosciences Secures $5.2 Million Seed Funding! 💵 Predicta Biosciences, a recent name to watch in the precision oncology space, has just secured an impressive $5.2 million in seed funding. Led by The Engine Ventures and backed by investments from Illumina Ventures, Time Boost Capital, the American Cancer Society Bright Edge, and the Oetgen family, this seed round is a big step forward for the company 🚀 Founded by top cancer genomics researchers and clinicians, Predicta is making strides with their non-invasive diagnostic for multiple myeloma. This innovative diagnostic tool aims to provide a better understanding of a patient's disease status through simple blood tests, replacing the more painful and invasive bone marrow biopsies. It's a promising development for both patients and the medical community, enabling easier monitoring and more tailored treatment plans 🔍 Predicta's first product, GenoPredicta, is already in use for research at Dana Farber Cancer Institute and will be launched commercially soon. The platform leverages advanced algorithmic analysis to help physicians determine the best treatment options, potentially enhancing patient outcomes and driving forward the field of precision medicine in cancer treatment. I'm certain this funding boost will set them to propel their progression even further! Top work Predicta Biosciences. #PredictaBiosciences #MultipleMyeloma #PrecisionOncology #InnovationInHealthcare #FundingSuccess #LifeScience #ElixirAssociates #StaffingPartner

🌐 Yesterday was #WorldCancerDay: let's unite in the fight against cancer and celebrate the strides we're making in healthcare innovation. 🎗️ Exciting times at TUM Venture Lab Healthcare as we continue to explore groundbreaking solutions and new treatment modalities. At TUM Venture Labs, we believe in the power of innovation to transform cancer care. 🚀 Our startup teams are dedicated to foster breakthroughs that go beyond traditional boundaries. By collaborating with visionary minds and leveraging cutting-edge technology, the TUM Venture Lab Healthcare is striving to help redefine the future of cancer treatment. 💡 From personalized therapies to advanced diagnostic tools to supporting patients on their cancer journey, we're on a mission to pioneer novel approaches that improve patient outcomes and quality of life. It's not just about treating cancer; it's about offering hope, resilience, and a brighter future for those affected. Join us in acknowledging the relentless efforts of researchers, healthcare professionals, organizations and also young startup teams who are dedicated to improve cancer care: Fusix Biotech GmbH - ExoSphere - ImuVeo - MelanOA - Microbeams - JustHealth - panthr healthtech - QTAS - Scentum #InnovationInHealthcare #CancerResearch #TUMVentureLabHealthcare #HealthcareInnovation #WorldCancerDay2024 🌍🩺

In this profile of #Madison #startup, AIQ Solutions, Isthmus Project details how AIQ founders, Glenn Liu and Robert Jeraj, of the UW Carbone Cancer Center, are utilizing software "to revolutionize the way oncologists manage the care of patients with metastatic disease." Their #technology, called 'TRAQinform IQ,' allows for the examination of individual tumor lesions to help physicians make more informed decisions about a patient's care, resulting in better outcomes. Liu and Jeraj got to this point as the result of a clinical trial, led by Pfizer, which "established the foundational science of AIQ’s technology — namely that (a) not every lesion responds similarly to #treatment, and (b) #drug resistance in just a small percentage of lesions can drive poor overall clinical outcomes." And AIQ attributes much of this success to the participants in their #clinicaltrials. “None of this would be possible without the many patients who volunteered to participate in the original and ongoing clinical trials,” Liu says. “Their commitment to help others ultimately made it possible for us to develop the imaging tools that resulted in today’s TRAQinform IQ product.” Article: 'Better, more customized care for late-stage cancer patients' https://lnkd.in/gDKkpMWr via Isthmus Project #university #Wisconsin #cancer #clinicalresearch #innovation

🌟 Another exciting event on 2 Bridge’s agenda! 🌟 Tomorrow, Eric Ciamporcero from our team is heading to the "R𝐞𝐜𝐞𝐧𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐭𝐨 𝐈𝐦𝐦𝐮𝐧𝐨-𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 (2𝐧𝐝 𝐞𝐝𝐢𝐭𝐢𝐨𝐧)" event, and we couldn't be more excited! Why is this event a must-attend? The program gathers world-renowned experts who will present their latest work in sessions focused on: - Car T Cells - Precision immuno-oncology - Immune-escape - Glycobiology in cancer - Cross-talk myeloid cells - Tumor-host interactions - Translational research At 2 Bridge, we're always on the lookout for innovative ways to push the boundaries in biotech. Eric's attendance at this event means we’re at the heart of the latest advancements, ready to transform cutting-edge research into real-world value. The revolution in cancer immunotherapy is here, and 2 Bridge is right in the mix—learning, contributing, and driving innovation to provide the best solutions to our clients. 💡🔥 #Biotech #ImmunoOncology #CancerResearch #TranslationalResearch #HealthcareInnovation #CancerImmunotherapy #ScientificAdvancements

Healthtech Startup 4baseCare Secures $6M to Enhance Cancer Care Solutions Healthtech startup 4baseCare has successfully secured $6 million in its latest funding round, spearheaded by Yali Capital, with participation from a group of undisclosed investors. This fresh injection of capital will be strategically utilized to enhance and expand 4baseCare’s product offerings, with a strong focus on advancing genomics and digital health solutions tailored for cancer care. The company has been at the forefront of developing personalized oncology solutions, aiming to bridge the gap in cancer care through innovative technology and research. This new funding will empower 4baseCare to accelerate its mission of providing cutting-edge cancer care solutions that are accessible and affordable. This milestone follows a $2 million Pre-Series A funding round in 2021, demonstrating the continued confidence and support from investors in the company’s vision and growth trajectory. #Healthtech #CancerCare #4baseCare #Genomics #DigitalHealth #StartupFunding #YaliCapital #Innovation #Healthcare #BPlanadvisors #Buildingbusinesses

🌍 Yesterday was World Cancer Day. One of the reasons I joined Sofinnova Partners is the firm's commitment to developing innovative solutions to fight this disease. Sofinnova's mission is to identify, create, finance, and develop the future champions of tomorrow, enabling thousands of patients to access new therapies.   📢 In December, shortly after I joined Sofinnova Partners, we announced a strategic alliance with Gustave Roussy, the leading European cancer center. The pairing puts Gustave Roussy's medical and scientific excellence together with our expertise in entrepreneurship to create a unique accelerator that should fuel the growth of oncology biotech startups. Our commitment doesn't stop there. We understand that collaboration is key to making a real impact in the fight against cancer, and we are actively seeking partnerships with like-minded organizations, researchers, and industry leaders to drive innovation and accelerate progress. 🤝 Together, we can make a difference in the lives of cancer patients and their families. Join us in our mission to transform cancer care and create a future where no one has to face this disease alone.   #WorldCancerDay #Innovation #Collaboration #entrepreneurship Sofinnova Partners Gustave Roussy Graziano Seghezzi Fabrice Barlesi Christophe Javaud Zhizhong "Joel" Y. Marie Duranteau